{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-151007","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2024-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.551040+00:00","generated_at":"2026-06-01T07:13:57.792231+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Interim CEO departs, CFO takes PEO role, new CCO, FDA immunobridging path","bullets":["Jeremy Gowler ceases as interim CEO, COO, CCO effective May 30; employment ends June 29.","CFO William Duke Jr. appointed principal executive officer; continues as CFO and principal accounting officer.","Timothy Lee appointed Chief Commercial Officer; previously led Amylyx sales ($390M revenue in 14 months).","FDA alignment on repeatable immunobridging pathway for serial mAbs COVID-19 EUAs; Est. clinical cost $25-40M per mAb."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-151007","json":"https://secwatch.observer/filing/0001193125-24-151007.json","markdown":"https://secwatch.observer/filing/0001193125-24-151007.md","text":"https://secwatch.observer/filing/0001193125-24-151007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000119312524151007/0001193125-24-151007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000119312524151007/d831636d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:13:57.792231+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"106ab082fc","claim":"William Duke, Jr. was appointed as Principal Executive Officer at Invivyd, Inc..","evidence_excerpt":"Effective May 30, 2024, William Duke, Jr., the Company’s Chief Financial Officer, will serve as the Company’s “principal executive officer”.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832038/000119312524151007/0001193125-24-151007-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Principal Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"89a022f018","claim":"Jeremy Gowler departed as Interim Chief Executive Officer, Chief Operating Officer and Chief Commercial Officer at Invivyd, Inc..","evidence_excerpt":"Jeremy Gowler, the Interim Chief Executive Officer, Chief Operating Officer and Chief Commercial Officer of Invivyd, Inc. (the “Company”), ceased serving as an executive officer and as the Company’s “principal executive officer,” effective as of May 30, 2024, with his employment terminating on June 29, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832038/000119312524151007/0001193125-24-151007-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Interim Chief Executive Officer, Chief Operating Officer and Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}